Danaher Corporation (DHR)
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-05
$226.34-3.66%
Close 2026-11-05 · 1-day change
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-05
QuarterlyIQ Insights · DHR
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-11-05.
The screen ranks DHR against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 4 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 42% for the rest of the cohort, n=10089).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Mr. Blair continued, “Looking ahead, continued end-market recovery and traction from our recent growth initiatives support our expectation to exit 2026 at a mid-single-digit core revenue growth rate.
Stated in 5 of 8 supplied quarters. Management reported: “For full year 2026, the Company expects non-GAAP core revenue will increase in the 3.0% to 4.0% range year-over-year.” “Mr. Blair continued, “Looking ahead, continued end-market recovery and traction from our recent growth initiatives support our expectation to exit 2026 at a mid-single-digit core revenue growth rate.” Revenue was $6.554 billion in 2026-Q3.
“Mr. Blair continued, “Looking ahead, continued end-market recovery and traction from our recent growth initiatives support our expectation to exit 2026 at a mid-single-digit core revenue growth rate.”
“On the top line, we continued on a steady recovery path with strength in Bioprocessing and better-than-expected performance in Life Sciences largely offsetting the impact of a lighter-than-typical Q1…”
“Mr. Blair continued, “Looking ahead, we expect the gradual improvement in our end markets we saw through 2025 to continue, and we believe the combination of our differentiated portfolio, the power of…”
“For full year 2025, there is no change to the Company’s expectation that non-GAAP core revenue will grow approximately 3% year-over-year.”
“For full year 2025, the Company expects that non-GAAP core revenue will increase approximately 3% year-over-year.”
The Company is also increasing its full year adjusted diluted net earnings per common share guidance to a range of $8.45 to $8.60 versus previous guidance of $8.35 to $8.55.
Stated in 5 of 8 supplied quarters. Management reported: “The Company is also increasing its full year adjusted diluted net earnings per common share guidance to a range of $8.45 to $8.60 versus previous guidance of $8.35 to $8.55.” “Rainer M. Blair, President and Chief Executive Officer, stated, “Our team executed well in the first quarter, which enabled us to accelerate innovation, drive productivity gains, and deliver nearly 10% adjusted EPS growth.”
We believe there are clear opportunities to enhance Masimo’s performance through DBS and our global scale.
Stated in 1 of 8 supplied quarters. Management reported: “We believe there are clear opportunities to enhance Masimo’s performance through DBS and our global scale.” “Mr. Blair continued, “We were also pleased to announce our intention to acquire Masimo Corporation, a leading provider of mission-critical pulse oximetry and patient monitoring solutions in acute care settings.”
“We believe there are clear opportunities to enhance Masimo’s performance through DBS and our global scale.”
Rainer M. Blair, President and Chief Executive Officer, stated, “Our team executed well in the first quarter, which enabled us to accelerate innovation, drive productivity gains, and deliver nearly 1…
Stated in 4 of 8 supplied quarters. Management reported: “Rainer M. Blair, President and Chief Executive Officer, stated, “Our team executed well in the first quarter, which enabled us to accelerate innovation, drive productivity gains, and deliver nearly 10% adjusted EPS growth.” “We’re investing in breakthrough innovation, enhancing our commercial execution, and driving meaningful productivity gains across our businesses.”
Looking forward, the opportunity for Danaher is clear: to become the defining leader in Life Sciences and Diagnostics–a company that unambiguously gains share, delivers sustainable profitable growth,…
Stated in 4 of 8 supplied quarters. Management reported: “Looking forward, the opportunity for Danaher is clear: to become the defining leader in Life Sciences and Diagnostics–a company that unambiguously gains share, delivers sustainable profitable growth, and helps our customers improve outcomes for patients around the world.”” “We’re investing in breakthrough innovation, enhancing our commercial execution, and driving meaningful productivity gains across our businesses.”
Over the trailing year it converted 1.44x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 52% of the time over the next year (vs 44% for the rest of the cohort, n=3371).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
17 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 46% of the time over the next year (vs 44% for the rest of the cohort, n=13229).
Not investment advice. As of 2026-11-05.
“The Company is also increasing its full year adjusted diluted net earnings per common share guidance to a range of $8.45 to $8.60 versus previous guidance of $8.35 to $8.55.”
“Rainer M. Blair, President and Chief Executive Officer, stated, “Our team executed well in the first quarter, which enabled us to accelerate innovation, drive productivity gains, and deliver nearly 1…”
“The Company is also initiating full year adjusted diluted net earnings per common share guidance in the range of $8.35 to $8.50.”
“The Company is also initiating full year adjusted diluted net earnings per common share guidance in the range of $7.60 to $7.75.”
“The transformation in our portfolio over the last several years has created a focused life sciences and diagnostics innovator, poised for higher long-term growth, expanded margins and stronger cash f…”
“Rainer M. Blair, President and Chief Executive Officer, stated, “Our team executed well in the first quarter, which enabled us to accelerate innovation, drive productivity gains, and deliver nearly 1…”
“We’re investing in breakthrough innovation, enhancing our commercial execution, and driving meaningful productivity gains across our businesses.”
“Our team also continued to execute very well, leveraging the Danaher Business System to accelerate innovation, drive share gains, and deliver meaningful productivity improvements.””
“The transformation in our portfolio over the last several years has created a focused life sciences and diagnostics innovator, poised for higher long-term growth, expanded margins and stronger cash f…”
“Looking forward, the opportunity for Danaher is clear: to become the defining leader in Life Sciences and Diagnostics–a company that unambiguously gains share, delivers sustainable profitable growth,…”
“We’re investing in breakthrough innovation, enhancing our commercial execution, and driving meaningful productivity gains across our businesses.”
“Our team also continued to execute very well, leveraging the Danaher Business System to accelerate innovation, drive share gains, and deliver meaningful productivity improvements.””
“The transformation in our portfolio over the last several years has created a focused life sciences and diagnostics innovator, poised for higher long-term growth, expanded margins and stronger cash f…”